Taiho Pharma Canada

Taiho Pharma Canada, Inc. is an oncology-focused pharmaceutical company engaged in the research, development, and manufacturing of innovative cancer treatments, alongside products in allergy/immunology and urology. Operating as part of the Otsuka Groupa global network of over 150 companies dedicated to improving health worldwideTaiho Pharma Canada... leverages decades of pharmaceutical expertise to address evolving cancer therapies and unmet medical needs. The company specializes in two primary oncology areas: advanced anti-metabolite chemotherapies and targeted small molecule inhibitors, building on a legacy that began with the 1974 release of Futraful (tegafur), establishing Taiho Pharmaceutical as a pioneer in oral anti-cancer agents. The company's oncology portfolio includes established products such as UFT (tegafur uracil) and TS-1 Capsules (tegafur, gimeracil, oteracil potassium), which represent cornerstone chemotherapy approaches refined through advanced technology and dedicated research. Beyond oncology, Taiho Pharma Canada extends its capabilities into allergy and immunology through anti-allergic drug development informed by research into IPD (suplatast tosilate), and into urology through treatments for urinary incontinence based on BUP-4 (propiverine hydrochloride) development. The company also manufactures nutrient tonics and crude drug gastrointestinal remedy products, diversifying its therapeutic footprint. Taiho Pharma Canada's competitive strengths center on its advanced technology infrastructure, incomparable research facilities, and dedicated investigator teams that enable rapid innovation cycles and the ability to optimize both established chemotherapy regimens and emerging targeted agents. This combination of deep oncology heritage, multi-therapeutic expertise, and access to Otsuka Group resources positions Taiho Pharma Canada to redefine cancer treatment approaches while addressing complementary therapeutic areas where unmet patient needs persist.Read More